EP Patent

EP2407169A1 — Combination formulations of anthracycline agents and cytidine analogs

Assigned to Jazz Pharmaceuticals Therapeutics Inc · Expires 2012-01-18 · 14y expired

What this patent protects

Provided is a composition suitable for parenteral administration to a subject, which composition comprises daunorubicin and cytarabine encapsulated in liposomes in a mole ratio of daunorubicin:cytarabine of about 1:5, wherein said liposomes have a mean diameter in the range of 4.…

USPTO Abstract

Provided is a composition suitable for parenteral administration to a subject, which composition comprises daunorubicin and cytarabine encapsulated in liposomes in a mole ratio of daunorubicin:cytarabine of about 1:5, wherein said liposomes have a mean diameter in the range of 4.5 nm to less than 250 nm; and wherein the pharmacokinetics of the composition are controlled by the liposomes, whereby the daunorubicin and cytarabine agents are to be delivered to a disease site in a coordinated fashion, thereby assuring that said ratio is maintained at the disease site.

Drugs covered by this patent

Patent Metadata

Patent number
EP2407169A1
Jurisdiction
EP
Classification
—
Expires
2012-01-18
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.